Related references
Note: Only part of the references are listed.Impact of Renin-Angiotensin-Aldosterone System-blocking Agents on the Risk of Contrast-induced Acute Kidney Injury: A Prospective Study and Meta-analysis
Feng Peng et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2015)
The J-Curve in Arterial Hypertension: Fact or Fallacy?
Evangelia P. Tsika et al.
CARDIOLOGY (2014)
Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension
Dylan Burger et al.
CLINICAL SCIENCE (2014)
The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease
J. J. Brugts et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
C5a and Bradykinin Receptor Cross-Talk Regulates Innate and Adaptive Immunity in Trypanosoma cruzi Infection
Veronica Schmitz et al.
JOURNAL OF IMMUNOLOGY (2014)
Blood pressure lowering and cardiovascular risk reply
Johan Sundstrom et al.
LANCET (2014)
Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes Mellitus AMeta-analysis
Jun Cheng et al.
JAMA INTERNAL MEDICINE (2014)
Angiotensin converting enzyme inhibitors v. angiotensin receptor blockers in the management of hypertension: A funder's perspective
J. L. Makkink et al.
SAMJ SOUTH AFRICAN MEDICAL JOURNAL (2014)
Efficacy and Safety of Combined vs. Single Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease: A Meta-Analysis
Paweena Susantitaphong et al.
AMERICAN JOURNAL OF HYPERTENSION (2013)
2013 ESH/ESC Guidelines for themanagement of arterial hypertension The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC)
Giuseppe Mancia et al.
JOURNAL OF HYPERTENSION (2013)
A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure
Gianluigi Savarese et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
A Systematic Review of Recent Clinical Practice Guidelines on the Diagnosis, Assessment and Management of Hypertension
Lubna A. Al-Ansary et al.
PLOS ONE (2013)
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of reninangiotensinaldosterone system inhibitors involving 158 998 patients
Laura C. van Vark et al.
EUROPEAN HEART JOURNAL (2012)
The Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas receptor axis: A potential target for treating thrombotic diseases
Rodrigo A. Fraga-Silva et al.
THROMBOSIS AND HAEMOSTASIS (2012)
AHA/ACCF Secondary Prevention and Risk REduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 Update - A Guideline from the American Heart Association and American College of Cardiology Foundation
Sidney C. Smith et al.
CIRCULATION (2011)
Influence of Time of Day of Blood Pressure-Lowering Treatment on Cardiovascular Risk in Hypertensive Patients With Type 2 Diabetes
Ramon C. Hermida et al.
DIABETES CARE (2011)
Bedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD
Ramon C. Hermida et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials
Sripal Bangalore et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents A Meta-Analysis
Ajay K. Gupta et al.
HYPERTENSION (2010)
Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway
Vijay Koka et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
S. Yusuf et al.
LANCET (2008)
Telmisartan, ramipril, or both in patients at high risk for vascular events
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: An 8-week uncontrolled trial
Roberto Minutolo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Emerging evidence for a functional angiotensin-converting - Enzyme 2-angiotensin-(1-7)-mas receptor axis more than regulation of blood pressure?
Mark C. Chappell
HYPERTENSION (2007)
Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor
EA Tallant et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
The realities of dyslipidaemia: what do the studies tell us?
JJP Kastelein
EUROPEAN HEART JOURNAL SUPPLEMENTS (2005)
Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease
J Emberson et al.
EUROPEAN HEART JOURNAL (2004)
Monitoring compliance in resistant hypertension: an important step in patient management
M Burnier et al.
JOURNAL OF HYPERTENSION (2003)
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack (Vol 358, pg 1033, 2001)
LANCET (2001)
Renal considerations in angiotensin converting enzyme inhibitor therapy - A statement for healthcare professionals from the council on the kidney in cardiovascular disease and the council for high blood pressure research of the American Heart Association
AC Schoolwerth et al.
CIRCULATION (2001)
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
S MacMahon et al.
LANCET (2001)
Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells
H Heitsch et al.
HYPERTENSION (2001)
Share Paper
